Compare VTEX & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTEX | ALLO |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 755.3M | 722.1M |
| IPO Year | 2019 | 2018 |
| Metric | VTEX | ALLO |
|---|---|---|
| Price | $3.52 | $1.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | $5.97 | ★ $8.35 |
| AVG Volume (30 Days) | 684.9K | ★ 4.8M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.78 | N/A |
| Revenue Next Year | $9.63 | $142,416.42 |
| P/E Ratio | $43.33 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.84 | $1.04 |
| 52 Week High | $4.73 | $4.46 |
| Indicator | VTEX | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 36.17 | 42.97 |
| Support Level | $3.45 | $1.87 |
| Resistance Level | $4.20 | $1.92 |
| Average True Range (ATR) | 0.13 | 0.11 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 25.00 | 5.71 |
Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. The VTEX platform is designed to be composable and complete, enabling its customers to seamlessly implement, optimize, test, and expand both B2C and B2B digital experiences. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).